SHIRE PLC - Elections for the interim dividend

PR Newswire
London, February 24

Elections for theinterim dividend in respect of the six months to December 31, 2016

February 24, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announced on February 16, 2017, an interim dividend of 25.70 US cents per Ordinary Share payable on April 25, 2017, to shareholders on the register ofmembers at the close of business on March 10, 2017.

Holders of Ordinary Shares are notified that, in order to receive UK sourced dividends via the Company's Income Access Share arrangements ("IAS Arrangements"), they need to have submitted a valid IAS Arrangements election form to the Company's Registrar, Equiniti, by no later than 5pm (GMT) on March 24, 2017.

Holders of Ordinary Shares are advised that:

• any previous elections made using versions of the IAS Arrangements election form in use prior to February 16, 2016, and any elections deemed to have been made prior to April 28, 2016, are no longer valid; and

• if they do not elect, or have not elected using the newly formatted IAS Arrangements election forms published on or after February 16, 2016, to receive UK sourced dividends via the Company's IAS Arrangements, their dividends will be Irish sourced and therefore incur Irish dividend withholding tax, subject to applicable exemptions.

  Internet links to the newly formatted IAS Arrangements election forms can be found at: http://investors.shire.com/shareholder-information/shareholder-forms.aspx

  For further information concerning the IAS Arrangements, please contact Equiniti ([phone]). If you are in any doubt as to what action to take, please consult your tax advisor immediately.

  Oliver Strawbridge

  Senior Assistant Company Secretary

For further information please contact:

Investor Relations
Ian Karp	[e-mail]	[phone]
Robert Coates	[e-mail]	[phone]
Media
Lisa Adler	[e-mail]	[phone]
Debbi Ford	[e-mail]	[phone]

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com